Show simple item record

dc.contributor.authorKrishna, Rajesh
dc.date.accessioned2022-01-28T12:33:29Z
dc.date.available2022-01-28T12:33:29Z
dc.date.issued2022
dc.identifier.citationPratt, G., El-Sharkawi, D., Kothari, J., D'Sa, S., Auer, R., McCarthy, H., Krishna, R., Miles, O., Kyriakou, C., & Owen, R. (2022). Guidelines on the diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. British journal of haematology, 10.1111/bjh.18036. Advance online publication. https://doi.org/10.1111/bjh.18036en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15119
dc.description.abstractScope: The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with Waldenström macroglobulinaemia. In individual patients, circumstances may dictate an alternative approach. Methodology: This guideline was compiled according to the British Society for Haematology (BSH) process at http://www.b-s-h.org.uk/guidelines/proposing-and-writing-a-new-bsh-guideline/. Recommendations are based on a review of the literature using Medline, Pubmed, Embase, Central, Web of Science searches from beginning of 2013 (since the publication of the previous guidelines) up to November 2021. The following search terms were used: Waldenström('s) macroglobulin(a)emia OR lymphoplasmacytic lymphoma, IgM(-related) neuropathy OR cold h(a)emagglutinin disease OR cold agglutinin disease OR cryoglobulin(a)emia AND (for group a only) cytogenetic OR molecular OR mutation OR MYD88 OR CXCR4, management OR treatment OR transfusion OR supportive care OR plasma exchange OR plasmapheresis OR chemotherapy OR bendamustine OR bortezomib OR ibrutinib OR fludarabine OR dexamethasone OR cyclophosphamide OR rituximab OR everolimus, bone marrow transplantation OR stem cell transplantation. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. Review of the manuscript was performed by the British Society for Haematology (BSH) Guidelines Committee Haemato-Oncology Task Force, the BSH Guidelines Committee and the Haemato-Oncology sounding board of BSH. It was also on the members section of the BSH website for comment. It has also been reviewed by UK Charity WMUK; these organisations do not necessarily approve or endorse the contents.
dc.description.urihttps://onlinelibrary.wiley.com/doi/10.1111/bjh.18036en_US
dc.language.isoenen_US
dc.subjectWaldenström macroglobulinaemiaen_US
dc.subjectguidelineen_US
dc.titleGuidelines on the diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guidelineen_US
dc.typeOtheren_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionVoRen_US
rioxxterms.versionofrecordhttps://doi.org/10.1111/bjh.18036en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.dateFCD2022-01-28T12:33:30Z
refterms.versionFCDVoR
refterms.dateFOA2022-01-28T12:33:30Z
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2022-01
html.description.abstractScope: The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with Waldenström macroglobulinaemia. In individual patients, circumstances may dictate an alternative approach. Methodology: This guideline was compiled according to the British Society for Haematology (BSH) process at http://www.b-s-h.org.uk/guidelines/proposing-and-writing-a-new-bsh-guideline/. Recommendations are based on a review of the literature using Medline, Pubmed, Embase, Central, Web of Science searches from beginning of 2013 (since the publication of the previous guidelines) up to November 2021. The following search terms were used: Waldenström('s) macroglobulin(a)emia OR lymphoplasmacytic lymphoma, IgM(-related) neuropathy OR cold h(a)emagglutinin disease OR cold agglutinin disease OR cryoglobulin(a)emia AND (for group a only) cytogenetic OR molecular OR mutation OR MYD88 OR CXCR4, management OR treatment OR transfusion OR supportive care OR plasma exchange OR plasmapheresis OR chemotherapy OR bendamustine OR bortezomib OR ibrutinib OR fludarabine OR dexamethasone OR cyclophosphamide OR rituximab OR everolimus, bone marrow transplantation OR stem cell transplantation. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. Review of the manuscript was performed by the British Society for Haematology (BSH) Guidelines Committee Haemato-Oncology Task Force, the BSH Guidelines Committee and the Haemato-Oncology sounding board of BSH. It was also on the members section of the BSH website for comment. It has also been reviewed by UK Charity WMUK; these organisations do not necessarily approve or endorse the contents.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


Files in this item

Thumbnail
Name:
Pratt 2022.pdf
Size:
331.8Kb
Format:
PDF
Description:
Full guideline

This item appears in the following Collection(s)

Show simple item record